<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03788538</url>
  </required_header>
  <id_info>
    <org_study_id>20181224</org_study_id>
    <nct_id>NCT03788538</nct_id>
  </id_info>
  <brief_title>Effects of Dexmedetomidine on Modulation of Perioperative Blood Glucose and Related Hormones</brief_title>
  <official_title>Effects of Dexmedetomidine on Modulation of Perioperative Blood Glucose and Related Hormones</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhuan Zhang</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators aimed to explore effects of dexmedetomidine on modulation of perioperative&#xD;
      blood glucose and relevant hormone during the general anesthesia with surgery time ≥ 4 hours,&#xD;
      and the effects on postoperative complications. 75 participants (American Society of&#xD;
      Anesthesiologists grades I or II, of both sexes,aged 40-80 yr,with BMI of 18.5-27 kg/m2)&#xD;
      scheduled for elective surgery under general anesthesia with surgery time ≥ 4 hours were&#xD;
      enrolled in this study. The participants were divided into four groups: group C (control&#xD;
      saline group, no dexmedetomidine use), group D1 (dexmedetomidine loading dose 1 mcg/kg,&#xD;
      maintenance dose 0.25 mcg/kg/h), group D2 (dexmedetomidine loading dose 1 mcg/kg, maintenance&#xD;
      dose 0.5 mcg/kg/h).10 minutes before anesthesia induction, all participants were&#xD;
      administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine&#xD;
      was changed to corresponding maintenance dose in each group. Blood samples were taken at the&#xD;
      beginning of dexmedetomidine (T0), the beginning of skin incision (T1), 1 h after skin&#xD;
      incision (T2), the end of the surgery (T3) and 1 h after patient transfer to PACU (T4) for&#xD;
      the value of blood glucose,lactate and relevant hormones. Also, investigators also record the&#xD;
      total amount of propofol and sufentanil at the end of surgery,and the complications within 24&#xD;
      h after the surgery.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 1, 2017</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effects of dexmedetomidine on perioperative blood glucose (mmol/L)</measure>
    <time_frame>before dexmedetomidine infusion, 1 hour after incision, at the end of surgery, 1 hour after patient transfer to postanesthesia care unit..</time_frame>
    <description>The changes of blood glucose during the surgery period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of dexmedetomidine on perioperative insulin (μIU/ml)</measure>
    <time_frame>before dexmedetomidine infusion, 1 hour after incision, at the end of surgery, 1 hour after patient transfer to postanesthesia care unit.</time_frame>
    <description>The changes of insulin during the surgery period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of dexmedetomidine on perioperative glucagon and catecholamine (pg/ml)</measure>
    <time_frame>before dexmedetomidine infusion, 1 hour after incision, at the end of surgery, 1 hour after patient transfer to postanesthesia care unit.</time_frame>
    <description>The changes of glucagon and catecholamine during the surgery period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effects of dexmedetomidine on perioperative cortisol (ng/ml)</measure>
    <time_frame>before dexmedetomidine infusion, 1 hour after incision, at the end of surgery, 1 hour after patient transfer to postanesthesia care unit.</time_frame>
    <description>The changes of cortisol during the surgery period</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>Dexmedetomidine</condition>
  <condition>Blood Glucose</condition>
  <arm_group>
    <arm_group_label>group 1 with no dexmedetomidine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 with dexmedetomidine 0.25μg/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2 with dexmedetomidine 0.5μg/kg/h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>dexmedetomidine</intervention_name>
    <description>10 minutes before anesthesia induction, all patients were administrated with dexmedetomidine 1 μg/kg/min.At the beginning of induction, dexmedetomidine was changed to corresponding maintenance dose in each group.</description>
    <arm_group_label>group 2 with dexmedetomidine 0.25μg/kg/h</arm_group_label>
    <arm_group_label>group 2 with dexmedetomidine 0.5μg/kg/h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        - patients undergoing operations over 4 h under general anesthesia,ASA physical status I or&#xD;
        II, irrespective of showing gender bias, aged between 50-75 years old, and having a body&#xD;
        mass index (BMI) between 18.5-28 kg/m2.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  the patients with bradycardia, hypoglycemia, heart disease, adrenal tumor,diabetes or&#xD;
             showed ≥7.0 mmol/L, or HbA1c level ≥6.5%.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the Affiliated Hospital of Yangzhou University, Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225012</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>December 25, 2018</study_first_submitted>
  <study_first_submitted_qc>December 26, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 27, 2018</study_first_posted>
  <last_update_submitted>January 29, 2021</last_update_submitted>
  <last_update_submitted_qc>January 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Zhuan Zhang</investigator_full_name>
    <investigator_title>Clinical Professor</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dexmedetomidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

